<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Surg</journal-id><journal-id journal-id-type="iso-abbrev">BMC Surg</journal-id><journal-id journal-id-type="pmc-domain-id">66</journal-id><journal-id journal-id-type="pmc-domain">bmcsurg</journal-id><journal-title-group><journal-title>BMC Surgery</journal-title></journal-title-group><issn pub-type="epub">1471-2482</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11251237</article-id><article-id pub-id-type="pmcid-ver">PMC11251237.1</article-id><article-id pub-id-type="pmcaid">11251237</article-id><article-id pub-id-type="pmcaiid">11251237</article-id><article-id pub-id-type="pmid">39014357</article-id><article-id pub-id-type="doi">10.1186/s12893-024-02494-0</article-id><article-id pub-id-type="publisher-id">2494</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Incidence and risk factors of new persistent opioid use after surgery and trauma: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6356-256X</contrib-id><name name-style="western"><surname>Gong</surname><given-names initials="J">Jiayi</given-names></name><address><email>Jay.gong@auckland.ac.nz</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1560-1186</contrib-id><name name-style="western"><surname>Jones</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1291-3902</contrib-id><name name-style="western"><surname>Chan</surname><given-names initials="AHY">Amy Hai Yan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03b94tp07</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution>School of Pharmacy, Faculty of Medical and Health Sciences, </institution><institution>The University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03b94tp07</institution-id><institution-id institution-id-type="GRID">grid.9654.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0372 3343</institution-id><institution>Department of Surgery, Faculty of Medical and Health Sciences, </institution><institution>The University of Auckland, </institution></institution-wrap>Auckland, New Zealand </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>24</volume><issue-id pub-id-type="pmc-issue-id">452330</issue-id><elocation-id>210</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>16</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-18 10:25:14.567"><day>18</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12893_2024_Article_2494.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Persistent opioid use (POU) can occur with opioid use after surgery or trauma. Current systematic reviews include patients with previous exposure to opioids, meaning their findings may not be relevant to patients who are opioid na&#239;ve (i.e. Most recent exposure was from surgery or trauma). The aim of this review was to synthesise narratively the evidence relating to the incidence of, and risk factors for POU in opioid-na&#239;ve surgical or trauma patients.</p></sec><sec><title>Method</title><p id="Par2">Structured searches of Embase, Medline, CINAHL, Web of Science, and Scopus were conducted, with final search performed on the 17th of July 2023. Searches were limited to human participants to identify studies that assessed POU following hospital admission due to surgery or trauma. Search terms relating to &#8216;opioid&#8217;, &#8216;analgesics&#8217;, &#8216;surgery&#8217;, &#8216;injury&#8217;, &#8216;trauma&#8217; and &#8216;opioid-related disorder&#8217; were combined. The Newcastle&#8211;Ottawa Scale for cohort studies was used to assess the risk of bias for studies.</p></sec><sec><title>Results</title><p id="Par3">In total, 22 studies (20 surgical and two trauma) were included in the analysis. Of these, 20 studies were conducted in the United States (US). The incidence of POU for surgical patients 18 and over ranged between 3.9% to 14.0%, and for those under 18, the incidence was 2.0%. In trauma studies, the incidence was 8.1% to 10.5% among patients 18 and over. Significant risk factors identified across surgical and trauma studies in opioid-na&#239;ve patients were: higher comorbidity burden, having pre-existing mental health or chronic pain disorders, increased length of hospital stay during the surgery/trauma event, or increased doses of opioid exposure after the surgical or trauma event. Significant heterogeneity of study design precluded meta-analysis.</p></sec><sec><title>Conclusion</title><p id="Par4">The quality of the studies was generally of good quality; however, most studies were of US origin and used medico-administrative data. Several risk factors for POU were consistently and independently associated with increased odds of POU, primarily for surgical patients. Awareness of these risk factors may help prescribers recognise the risk of POU after surgery or trauma, when considering continuing opioids after hospitalisation. The review found gaps in the literature on trauma patients, which represents an opportunity for future research.</p></sec><sec><title>Trial registration</title><p id="Par5">PROSPERO registration:&#160;CRD42023397186.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12893-024-02494-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Surgery</kwd><kwd>Trauma</kwd><kwd>Opioids</kwd><kwd>Persistent opioid use</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001505</institution-id><institution>Health Research Council of New Zealand</institution></institution-wrap></funding-source><award-id>21/056</award-id><principal-award-recipient><name name-style="western"><surname>Gong</surname><given-names>Jiayi</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Auckland Academic Health Alliance, New Zealand</institution></funding-source><award-id>8753</award-id><principal-award-recipient><name name-style="western"><surname>Gong</surname><given-names>Jiayi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par6">Persistent opioid use (POU) in patients who have been admitted to hospital for surgery or trauma is a growing area of interest, due to the common use of opioids as a mainstay treatment of acute pain [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. POU is defined in most studies as continued opioid use beyond 90&#160;days after surgery or trauma with the definition adapted from diagnostic criteria for chronic pain [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Much of the literature on POU has been in the post-surgical context, with few studies in trauma, and even fewer focusing on risk of POU development in opioid-na&#239;ve patients [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Previous systematic reviews have mostly focused on patients regardless of any recent exposures to opioids prior to surgery [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Patients with a recent history of opioid use before hospital admission may indicate chronic opioid usage, and have important differences in terms of risk factors for POU characteristics and opioid needs compared to opioid-na&#239;ve patients [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Patients with prior opioid use and subsequent continuation of opioids after hospitalisation may also represent opioid use for therapeutic indications related to non-surgical and non-trauma indications [<xref ref-type="bibr" rid="CR3">3</xref>]. This represents an important gap in the literature, and a review focusing on opioid-na&#239;ve patients after surgery or trauma would be informative.</p><p id="Par7">POU may be a useful marker in detecting harm such as opioid misuse and mortality after surgery or trauma [<xref ref-type="bibr" rid="CR3">3</xref>]. A recent study from the United States (US) by <italic toggle="yes">Santosa </italic>et al<italic toggle="yes">.</italic> reported persistent opioid users after surgery have a higher risk of mortality (Hazard Ratio (HR) 3.44; 95% confidence interval (CI) 2.99&#8211;3.96) and opioid-related readmissions and visits to the emergency department (adjusted odds ratio (aOR) 1.68; 95% CI 1.55&#8211;1.82) after adjusting for important clinical and demographic covariates [<xref ref-type="bibr" rid="CR11">11</xref>]. Thus, identifying risk factors related to POU may be key for informing policymakers and stakeholders in minimising and preventing harm related to POU.</p><p id="Par8">The aim of this systematic review is to synthesise the current literature on POU in opioid-naive patients after surgery or trauma and risk factors for POU.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Search strategy</title><p id="Par9">A systematic search was first carried out on the 18th of January 2023 and a final search was carried out on the 17th of July 2023. A structured search of the following databases was undertaken using the OVID platform for Embase (1980 to current) and Medline (1946 to current), Cumulative Index to Nursing and Allied Health Literature (CINAL Plus) hosted on the EBSCO website from 1937 to the present, Web of Science provided by Clarivate, and Scopus. Previously published reviews on the topic were used to inform the search strategy and search terms. Reference lists of previous studies were used to identify relevant studies via the snowballing (pearl-growing) method [<xref ref-type="bibr" rid="CR12">12</xref>]. Keywords relating to opioids, surgery, trauma, analgesia, persistent opioid and opioid dependence were used to construct the search strategy. Reporting of this review was according to 2020 PRISMA statement [<xref ref-type="bibr" rid="CR13">13</xref>]. The specific search terms and strategies for the respective databases are in the supplementary material- Part 1.</p><p id="Par10">Searches were limited to human participants. No limits were placed on the publication date. Conference proceedings and grey literature were excluded.</p></sec><sec id="Sec4"><title>Study selection</title><p id="Par11">The following inclusion criteria were used for selection of studies in this systematic review: 1) the study included patients that were admitted to the hospital with trauma or had undergone surgery; 2) all patients included in the primary analysis were opioid-na&#239;ve e.g. no recent exposure to opioids, as defined by the study; 3) POU must be measured as an outcome &#8211; defined as <italic toggle="yes">any</italic> initial opioid exposure following the surgery or trauma event around 30&#160;days of the event (either on discharge or before the event), then subsequent re-exposure to <italic toggle="yes">any</italic> opioids from 90&#160;days after the event; and 4) the duration of assessment of POU does not exceed 365&#160;days after the event. There must be only two time periods associated with the definition of POU, one for initiation related to the event (30&#160;days prior to and, up to 30&#160;days after the event) and subsequent re-exposure (90&#160;days after the event, up to 365&#160;days). The rationale for these two time periods was that without the initial opioid exposure immediately before or after the event, subsequent opioid prescription may be unrelated to either surgery or trauma and does not represent POU. In addition, any additional criteria on opioid use will result in exclusion as per below.</p><p id="Par12">We excluded the following types of studies:<list list-type="bullet"><list-item><p id="Par13">Studies with a POU definition that included any criteria specifying a threshold for a number of prescriptions dispensed or filled by a pharmacy during any of the two main time points e.g. need to fill more than one prescription at either time points.</p></list-item><list-item><p id="Par14">Studies with a POU definition that included criteria specifying a threshold for quantity or duration of opioid supply at the two time points e.g. need to fill more than 30&#160;days&#8217; supply at either time points.</p></list-item><list-item><p id="Par15">Studies with a POU definition that specified the need for any opioid exposure in addition to the two-time frames mentioned above e.g. If a further prescription needs to be collected between 30 and 90&#160;days after the event.</p></list-item><list-item><p id="Par16">Studies that did not specify or include a fixed period for the assessment of POU i.e. open follow-up period after 90&#160;days.</p></list-item><list-item><p id="Par17">Studies that only included patients undergone dental, or aesthetics/body contouring procedures due to heterogeneity in pain management and patient population.</p></list-item></list></p><p id="Par18">Exposure to opioids was defined as any evidence that the patient may have received opioids from either prescription or community pharmacy dispensing records, or from patient interviews during the follow-up period.</p></sec><sec id="Sec5"><title>Study review and classification</title><p id="Par19">EndNote Library (EndNote X9 Thomson Reuters, New York, NY, US) and Rayyan (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rayyan.qcri.org">http://rayyan.qcri.org</ext-link>) [<xref ref-type="bibr" rid="CR14">14</xref>] were used to manage the citations. Two researchers (JG, AHYC) screened the titles and abstracts of all identified citations; full texts were obtained for any potentially eligible studies or abstracts that did not have sufficient information for review. Studies that did not meet the inclusion criteria or had reasons for exclusion at this review stage were not reviewed further, with reasons for exclusion documented. Any study was classified as trauma-related if trauma was the main cause of hospitalisation (e.g. Ankle fracture) irrespective of the occurrence of any surgery. Otherwise, any study was considered to be surgical-related, if surgery was the main exposure.</p></sec><sec id="Sec6"><title>Data extraction</title><p id="Par20">We developed a standardised pilot-tested data extraction form (Microsoft Excel 2023, Microsoft Corporation, Washington, US). The following variables from each of the studies were extracted:<list list-type="bullet"><list-item><p id="Par21">General study information (author, year of publication, country of origin)</p></list-item><list-item><p id="Par22">Study design (age restriction, inclusion/exclusion criteria)</p></list-item><list-item><p id="Par23">Type and years of data used (institutional, linked administrative data)</p></list-item><list-item><p id="Par24">Study population (surgery or trauma, related specialities, number of participants in primary analysis)</p></list-item><list-item><p id="Par25">POU definition</p></list-item><list-item><p id="Par26">Incidence of POU</p></list-item><list-item><p id="Par27">Risk factors for POU</p></list-item></list></p></sec><sec id="Sec7"><title>Quality assessment and risk of <italic toggle="yes">bias</italic></title><p id="Par28">The Newcastle&#8211;Ottawa Scale (NOS) for cohort studies was used to assess the risk of bias for studies. Good quality studies had three or four stars in the selection domain <italic toggle="yes">and</italic> one or two stars in the comparability domain <italic toggle="yes">and</italic> 2 or 3 stars in the outcome domain. Fair quality studies had two stars in the selection domain <italic toggle="yes">and</italic> 1 or 2 stars in the comparability domain <italic toggle="yes">and</italic> 2 or 3 stars in the outcome or the exposure domain. Poor quality studies had zero or one star in either the selection <italic toggle="yes">or</italic> the outcome domain <italic toggle="yes">or</italic> zero stars in the compatibility domain [<xref ref-type="bibr" rid="CR15">15</xref>]. The NOS has been widely used to assess the risk of bias in other systematic reviews, and it has been shown to correlate well with the Cochrane Collaboration's recommended risk of bias assessment tool, the Robins-I [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec8"><title>Analysis</title><p id="Par29">Data were synthesised narratively. The main outcome on the incidence of POU was reported as the percentage and absolute crude number of the final cohort included for analysis. We examined potential risk factors based on several categories: sociodemographic, baseline comorbidities, baseline medication use, inpatient variables, and any prescribing practice on discharge. The effect size of risk factors for POU was reported as aORs with 95% CI if P&#8201;&lt;&#8201;0.05, where suitable. Due to the heterogeneity in study characteristics, patient groups and measurement of risk factors, a meta-analysis was not able to be performed.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par30">A total of 7,932 hits were retrieved from the initial search. Sixty-five entries were eligible for full-text screening. After full text review, another 43 references were excluded, leaving a final of 22 studies which met the inclusion criteria (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Flowchart for study selection. <bold>a</bold> Automated removal of duplicates done via Rayyan. <bold>b</bold> Entry was a review (<italic toggle="yes">n</italic>&#8201;=&#8201;7), meta-analyses (<italic toggle="yes">n</italic>&#8201;=&#8201;3), or consensus statement (<italic toggle="yes">n</italic>&#8201;=&#8201;1). <bold>c</bold> Persistent opioid use</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12893_2024_2494_Fig1_HTML.jpg"/></fig></p><p id="Par31">The characteristics of included studies are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The 22 studies included 20 surgical and two trauma studies. All studies were retrospective and most (21/22) studies used medico-administrative data (e.g. Medicare or commercial insurance claims). Out of 20 surgical studies, 18 originated from the US. Both trauma studies were conducted in the US.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Characteristics of all included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study (author, year and country of origin)</th><th align="left" colspan="1" rowspan="1">Study design (retrospective/prospective, main inclusion and exclusion criteria)</th><th align="left" colspan="1" rowspan="1">enrolment period and data type</th><th align="left" colspan="1" rowspan="1">POU definition</th><th align="left" colspan="1" rowspan="1">Study population (surgery/trauma, subspecialty)</th><th align="left" colspan="1" rowspan="1">Number of patients (in analysis, POU incidence)</th><th align="left" colspan="1" rowspan="1">Significant risk factors (adjusted odds ratios (aOR); 95% confidence interval (CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Johnson et al</p><p>2016</p><p>United States [<xref ref-type="bibr" rid="CR18">18</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions:</p><p>Opioid exposure 11&#160;months prior</p><p>Diagnosis of opioid dependence or abuse 12&#160;months prior</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to December 2012</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Trauma</p><p>Hand</p></td><td align="left" colspan="1" rowspan="1"><p>59,725</p><p>POU: 6,272 (10.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>&#8201;&#8805;&#8201;65 age (vs 18&#8211;34): aOR&#8201;=&#8201;0.8; 95% CI 0.7&#8211;0.9</p><p>Female: aOR&#8201;=&#8201;1.10; 95% CI 1.00&#8211;1.10</p><p>&#8201;&#8805;&#8201;70&#160;ka income: aOR&#8201;=&#8201;0.70; 95% CI 0.60&#8211;0.90</p><p>Elixhauser comorbidity index:</p><p>2 (vs 0 or 1): aOR&#8201;=&#8201;1.30; 95% CI 1.30&#8211;1.50</p><p>&#8201;&gt;&#8201;3 (vs 0 or 1): aOR&#8201;=&#8201;2.20; 95% CI 2.00&#8211;2.30</p><p>Mental health disorders: aOR&#8201;=&#8201;1.10; 95% CI 1.00&#8211;1.20 Tobacco abuse: aOR&#8201;=&#8201;1.60; 95% CI 1.00&#8211;2.60</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Brummet et al. 2017</p><p>United States [<xref ref-type="bibr" rid="CR19">19</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 18 to 64</p><p>Exclusions:</p><p>Opioid exposure 11&#160;months prior</p><p>Sequential anesthsia postoperatively</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p></td><td align="left" colspan="1" rowspan="1"><p>January 2012 to June 2015</p><p>Medico-administrative (Clinformatic)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after discharge, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>13 elective procedures</p></td><td align="left" colspan="1" rowspan="1"><p>36,177</p><p>POU:</p><p>2,187 (6.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>40&#8211;49 age (vs 18&#8211;29): aOR&#8201;=&#8201;0.72; 95% CI 0.61&#8211;0.84</p><p>High school Education (vs college):</p><p>aOR&#8201;=&#8201;1.22 95% CI 1.04&#8211;1.43</p><p>Charlson comorbidity: aOR&#8201;=&#8201;1.10; 95% CI 1.08&#8211;1.13 History of tobacco use: aOR&#8201;=&#8201;1.35; 95% CI 1.21&#8211;1.49 Anxiety: aOR&#8201;=&#8201;1.25; 95% CI 1.10&#8211;1.42</p><p>Mood: aOR&#8201;=&#8201;1.15; 95% CI 1.01&#8211;1.30</p><p>Alcohol/substance abuse: aOR&#8201;=&#8201;1.34; 95% CI 1.05&#8211;1.72 Pain disorders: aOR&#8201;=&#8201;1.39; 95% CI 1.26&#8211;1.54</p><p>Back pain: aOR&#8201;=&#8201;1.57; 95% CI 1.42&#8211;1.75</p><p>Neck pain: aOR&#8201;=&#8201;1.22; 95% CI 1.07&#8211;1.39</p><p>Arthritis: aOR&#8201;=&#8201;1.93; 95% CI 1.71&#8211;2.19</p><p>Perioperative OME<sup>b</sup> received&#8201;&#8805;&#8201;300&#160;mg:</p><p>aOR&#8201;=&#8201;1.14; 95% CI 1.03&#8211;1.27</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lee et al</p><p>2017</p><p>United States [<xref ref-type="bibr" rid="CR20">20</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions:</p><p>Opioid exposure 11&#160;months prior</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p><p>Subsequent procedure within 6&#160;months</p><p>Discharged to home hospice care</p><p>Died during hospitalisation</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to June 2014</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after discharge, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Cancer-related surgery</p></td><td align="left" colspan="1" rowspan="1"><p>39,877</p><p>POU:</p><p>4,159 (10.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Breast cancer surgery:</p><p>Age: aOR&#8201;=&#8201;0.99; 95% CI 0.99&#8211;1.00</p><p>SUD<sup>c</sup>: aOR&#8201;=&#8201;1.39; 95% CI 1.13&#8211;1.70</p><p>Elixhauser comorbidity score:</p><p>aOR&#8201;=&#8201;1.02; 95% CI 1.01&#8211;1.02</p><p>Median income (vs 60-70&#160;k)&#8201;&#8805;&#8201;70&#160;k:</p><p>aOR&#8201;=&#8201;0.87; 95% CI 0.79&#8211;0.97</p><p>Colorectal surgery:</p><p>Elixhauser comorbidity score:</p><p>aOR&#8201;=&#8201;1.02; 1.01- 1.03</p><p>Median income (vs 60-70&#160;k)&#8201;&#8805;&#8201;70&#160;k:</p><p>aOR&#8201;=&#8201;0.75; 95% CI 0.61&#8211;0.93</p><p>Thoracic surgery:</p><p>Female: aOR&#8201;=&#8201;0.73; 95% CI 0.59&#8211;0.91</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Harbaugh et al</p><p>2018</p><p>United States [<xref ref-type="bibr" rid="CR21">21</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 13 to 21</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Subsequent procedure within 6&#160;months</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to December 2014</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>13 Paediatric specialties</p></td><td align="left" colspan="1" rowspan="1"><p>88,637</p><p>POU:</p><p>4,267 (4.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age: aOR&#8201;=&#8201;1.07; 95% CI 1.05&#8211;1.08</p><p>Female: aOR&#8201;=&#8201;1.22; 95% CI 1.14&#8211;1.31</p><p>SUD: aOR&#8201;=&#8201;1.41; 95% CI 1.12&#8211;1.77</p><p>Chronic pain: aOR&#8201;=&#8201;1.48; 95% CI 1.33&#8211;1.66</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bennet et al</p><p>2018</p><p>United States [<xref ref-type="bibr" rid="CR22">22</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 8 to 25</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior to surgery</p><p>Subsequent procedure within 6&#160;months</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to December 2014</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Cleft-related</p></td><td align="left" colspan="1" rowspan="1"><p>2,034</p><p>POU:</p><p>90 (4.4%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age: aOR&#8201;=&#8201;1.11; 95% CI 1.04&#8211;1.17</p><p>Paediatric chronic conditions</p><p>Gastrointestinal: aOR&#8201;=&#8201;7.37; 95% CI 1.49&#8211;36.54</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Brescia et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR23">23</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior to surgery</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p><p>Subsequent procedure within 6&#160;months</p><p>Discharged to home hospice care</p><p>Died during hospitalisation</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to June 2014</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after discharge, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Lung-resection</p></td><td align="left" colspan="1" rowspan="1"><p>3,026</p><p>POU:</p><p>424 (14.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age&#8201;&lt;&#8201;64: aOR&#8201;=&#8201;1.30; 95% CI 1.05&#8211;1.62</p><p>Male: aOR&#8201;=&#8201;1.39; 95% CI 1.12&#8211;1.72</p><p>Length of stay&#8201;&gt;&#8201;5&#160;days: aOR&#8201;=&#8201;1.30; 95% CI 1.04&#8211;1.63</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Brescia et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR24">24</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;65</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior to surgery</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p><p>Subsequent procedure within 6&#160;months</p></td><td align="left" colspan="1" rowspan="1"><p>January 2009 to June 2015</p><p>Medico-administrative (Medicare)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after discharge, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Cardiothoracic</p></td><td align="left" colspan="1" rowspan="1"><p>24,549</p><p>POU:</p><p>3,153 (12.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Length of stay: aOR&#8201;=&#8201;1.03; 95% CI 1.02&#8211;1.04</p><p>Perioperative OME: aOR&#8201;=&#8201;1.00; 95% CI 1.00&#8211;1.00</p><p>Age: aOR&#8201;=&#8201;0.99; 95% CI 0.98&#8211;1.00</p><p>Female: aOR&#8201;=&#8201;1.14; 95% CI 1.04&#8211;1.25</p><p>African American: aOR&#8201;=&#8201;1.50; 95% CI 1.04&#8211;1.25 Charlson comorbidity (vs 0,1,2)</p><p>3,4: aOR&#8201;=&#8201;1.14; 95% CI 1.02&#8211;1.26</p><p>5,6: aOR&#8201;=&#8201;1.31; 95 CI 1.16&#8211;1.48</p><p>Tobacco use: aOR&#8201;=&#8201;1.10; 95% CI 1.01&#8211;1.20</p><p>substance use: aOR&#8201;=&#8201;1.31; 95% CI 1.05&#8211;1.63</p><p>Back pain: aOR&#8201;=&#8201;1.27; 95% CI 1.16&#8211;1.38</p><p>Arthritis: aOR&#8201;=&#8201;1.13; 95% CI 1.04&#8211;1.23</p><p>Other pain disorder: aOR&#8201;=&#8201;1.10; 95% CI 1.02&#8211;1.19</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Thiels et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR25">25</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;65</p><p>Exclusions</p><p>Opioid exposure 6&#160;months prior</p><p>Treatment for opioid use disorder by buprenorphine or methadone 90&#160;days after surgery</p><p>Multiple procedure on the same day</p><p>Length of stay&#8201;&gt;&#8201;7&#160;days</p><p>Admitted as inpatient 1&#160;day before surgery</p><p>Cancer patients receiving non-cancer surgeries</p><p>Patients receiving hospice care</p><p>Discharged to a skilled nursing facility on the day of discharge</p></td><td align="left" colspan="1" rowspan="1"><p>January 2009 to June 2018</p><p>Medico-administrative (Optumlab)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 7&#160;days before and after discharge, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>20 commonly performed procedures</p></td><td align="left" colspan="1" rowspan="1"><p>444,764</p><p>POU:</p><p>31,431 (7.1%)</p></td><td align="left" colspan="1" rowspan="1"><p>Female: aOR&#8201;=&#8201;1.22; 95% CI 1.19&#8211;1.26</p><p>Ethnicity (vs white):</p><p>African American: aOR&#8201;=&#8201;1.25; 95% CI 1.20&#8211;1.30, Asian: aOR&#8201;=&#8201;0.80; 95% CI 0.72&#8211;0.88</p><p>Age 45&#8211;54 (vs 18&#8211;24): aOR&#8201;=&#8201;1.28; 95% CI 1.18&#8211;1.38) Age 65&#8211;74: aOR&#8201;=&#8201;1.29; 95% CI 1.17&#8211;1.43</p><p>OME 500 (vs 1&#8211;199): aOR&#8201;=&#8201;1.20; 95% CI 1.14&#8211;1.26</p><p>Alcohol misuse: aOR&#8201;=&#8201;1.45; 95% CI 1.23&#8211;1.78</p><p>Substance misuse aOR&#8201;=&#8201;1.47; 95% CI 1.11&#8211;1.95 Depression: aOR&#8201;=&#8201;1.41; 95% CI 1.32&#8211;1.50</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Roughead et al</p><p>2019</p><p>Australia [<xref ref-type="bibr" rid="CR26">26</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 18 to 100</p><p>Exclusions</p><p>Opioid exposure 6&#160;months prior</p><p>Died during hospital admission</p></td><td align="left" colspan="1" rowspan="1"><p>January 2014 to December 2015</p><p>Medico-administrative (Veteran&#8217;s Affairs)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 2&#160;days before and 7&#160;days after discharge, additional dispensing of any opioids 90 to 365&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>14 different specialities</p></td><td align="left" colspan="1" rowspan="1"><p>3,907</p><p>POU:</p><p>153 (3.9%)</p></td><td align="left" colspan="1" rowspan="1">N/A</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Berger et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR27">27</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: Adult</p><p>Exclusions:</p><p>Opioid exposure 150&#160;days prior</p><p>Subsequent procedure within 30&#160;days or 365&#160;days of index procedure</p><p>Greater than 2 opioid refills prior</p><p>Discharged to a facility</p></td><td align="left" colspan="1" rowspan="1"><p>October 2010 to September 2014</p><p>Medico-administrative (Optumlab)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 7&#160;days after discharge, additional dispensing of any opioids 91 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Urological</p></td><td align="left" colspan="1" rowspan="1"><p>38,689</p><p>POU:</p><p>2,399 (6.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Female: aOR&#8201;=&#8201;1.32; 95% CI 1.13&#8211;1.55</p><p>Length of stay: aOR&#8201;=&#8201;1.05; 95% CI 1.02&#8211;1.08</p><p>Elixhauser comorbidity&#8201;&#8805;&#8201;3:</p><p>aOR&#8201;=&#8201;1.42; 95% CI 1.22&#8211;1.66</p><p>Mental health disorders: aOR&#8201;=&#8201;1.37; 95% CI 1.23&#8211;1.52 Chronic Pain: aOR&#8201;=&#8201;1.40; 95% CI 1.11&#8211;1.78</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Gil et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR28">28</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Subequent procedure within 6&#160;months</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p><p>Not discharged home</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to March 2015</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Orthopaedic</p></td><td align="left" colspan="1" rowspan="1"><p>104,154</p><p>POU:</p><p>8,686 (8.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age 18&#8211;29 (vs 50&#8211;59): aOR&#8201;=&#8201;0.68; 95% CI 0.61&#8211;0.76</p><p>Age&#8201;&gt;&#8201;70: aOR&#8201;=&#8201;0.90; 95% CI 0.81&#8211;0.99</p><p>Female: aOR&#8201;=&#8201;1.26; 95% CI 1.20&#8211;1.32</p><p>Median income 50&#160;k-59&#160;k (vs&#8201;&gt;&#8201;70&#160;K):</p><p>aOR&#8201;=&#8201;1.10; 95% CI 1.03&#8211;1.17</p><p>Anxiety: aOR&#8201;=&#8201;1.17; 95% CI 1.07&#8211;1.28</p><p>Charlson comorbidity: aOR&#8201;=&#8201;1.11; 95% CI 1.09&#8211;1.13</p><p>Mood disorder: aOR&#8201;=&#8201;1.29; 95% CI 1.19&#8211;1.40 Suicide/self-harm: aOR&#8201;=&#8201;1.97; 1.29&#8211;3.42</p><p>Alcohol misuse: aOR&#8201;=&#8201;1.57; 95% CI 1.30&#8211;1.89</p><p>Back pain: aOR&#8201;=&#8201;1.09; 95% CI 1.03&#8211;1.15</p><p>Neck Pain: aOR&#8201;=&#8201;1.12; 95% CI 1.05&#8211;1.19</p><p>Perioperative OME (&gt;&#8201;743&#160;mg):</p><p>aOR&#8201;=&#8201;2.00; 95% CI 1.91&#8211;2.10</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Wright et al. 2019</p><p>United States [<xref ref-type="bibr" rid="CR29">29</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 18 to 64</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Subequent procedure within 6&#160;months</p></td><td align="left" colspan="1" rowspan="1"><p>2009 to 2016</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Gynaecology</p></td><td align="left" colspan="1" rowspan="1"><p>438,039</p><p>POU:</p><p>29,643 (6.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age 18&#8211;29 (vs 40&#8211;49): aOR&#8201;=&#8201;1.22; 95% CI 1.17&#8211;1.28 Elixhauser comorbiditiy&#8201;&gt;&#8201;2:</p><p>aOR&#8201;=&#8201;1.20; 95% CI1.14&#8211;1.25)</p><p>Mental health disorders: aOR&#8201;=&#8201;1.14; 95% CI 1.09&#8211;1.19 Anxiety: aOR&#8201;=&#8201;1.15; 95% CI 1.11&#8211;1.20</p><p>SUD: aOR&#8201;=&#8201;1.41; 95% CI 1.34&#8211;1.48 Total perioperative OME 200&#8211;299 (vs 135):</p><p>aOR&#8201;=&#8201;1.16; 95% CI 1.10&#8211;1.22</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bicket et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR30">30</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 18 to 64</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Additional procedure 30&#160;days before to 14&#160;days after</p></td><td align="left" colspan="1" rowspan="1"><p>January 2010 to December 2015</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Unspecified</p></td><td align="left" colspan="1" rowspan="1"><p>912,882</p><p>POU:</p><p>93,159 (10.2%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age 40&#8211;49 (vs 18&#8211;29): aOR&#8201;=&#8201;1.18; 95% CI 1.15&#8211;1.21 Female: aOR&#8201;=&#8201;1.15; 95% CI 1.13&#8211;1.17</p><p>Smoking: aOR&#8201;=&#8201;1.25; 95% CI 1.22&#8211;1.29</p><p>Charlson: aOR&#8201;=&#8201;1.16; 95% CI 1.15&#8211;1.17</p><p>Anxiety: aOR&#8201;=&#8201;1.15; 95% CI 1.13&#8211;1.18</p><p>Mood: aOR&#8201;=&#8201;1.27; 95% CI 1.24&#8211;1.30</p><p>Alcohol misuse: aOR&#8201;=&#8201;1.22; 95% CI 1.13&#8211;1.30</p><p>substance misuse: aOR&#8201;=&#8201;1.40; 95% CI 1.30&#8211;1.52</p><p>Back pain: aOR&#8201;=&#8201;1.18; 95% CI 1.16&#8211;1.20</p><p>Neck pain: aOR&#8201;=&#8201;1.07; 95% CI 1.05&#8211;1.10)</p><p>Arthritis: aOR&#8201;=&#8201;1.20; 95% CI 1.18&#8211;1.22)</p><p>Total perioperative OME: aOR&#8201;=&#8201;1.05; 95% CI 1.03&#8211;1.07</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Gossett et al</p><p>2019</p><p>United States [<xref ref-type="bibr" rid="CR31">31</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: 18 to 64</p><p>Exclusions</p><p>Opioid exposure 12&#160;months prior</p><p>Multiple procedure</p><p>Subsequent procedure within 6&#160;months</p><p>Admitted with multiple trauma</p></td><td align="left" colspan="1" rowspan="1"><p>January 2009 to June 2016</p><p>Medico-administrative (Optumlab)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 14&#160;days before and seven days after surgery, additional dispensing of any opioids 91 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Trauma</p><p>Ankle fracture</p></td><td align="left" colspan="1" rowspan="1"><p>13,088</p><p>POU:</p><p>1,061 (8.1%)</p></td><td align="left" colspan="1" rowspan="1"><p>Female: aOR&#8201;=&#8201;1.16; 95% CI 1.01&#8211;1.34</p><p>Income&#8201;&gt;&#8201;100&#160;K (vs 60&#160;K-74&#160;K):</p><p>aOR&#8201;=&#8201;0.73; 95% CI 0.58&#8211;0.90</p><p>Total perioperative OME (&gt;&#8201;650&#160;mg):</p><p>aOR&#8201;=&#8201;1.56; 95% CI 1.34&#8211;1.82</p><p>Charlson score&#8201;&gt;&#8201;5 (vs 0): aOR&#8201;=&#8201;1.92; 95% CI 1.19&#8211;3.09 Tobacco use: aOR&#8201;=&#8201;1.37; 95% CI 1.17&#8211;1.60</p><p>Anxiety: aOR&#8201;=&#8201;1.57; 95% CI 1.30&#8211;1.90</p><p>Mood: aOR&#8201;=&#8201;1.25; 95% CI 1.05&#8211;1.50</p><p>Substance misuse: aOR&#8201;=&#8201;1.33; 95% CI 1.01&#8211;1.75</p><p>Arthritis: aOR&#8201;=&#8201;0.56; 95% CI 0.43&#8211;0.72</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ward et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR32">32</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8804;&#8201;18</p><p>Exclusions</p><p>Opioid exposure 90&#160;days prior</p><p>Without anesthesia code</p><p>Additional anesthetic code within 365&#160;days</p><p>Length of stay&#8201;&#8805;&#8201;30&#160;days</p></td><td align="left" colspan="1" rowspan="1"><p>December 2002 to December 2017</p><p>Medico-administrative (Optumlab)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Paediatric</p></td><td align="left" colspan="1" rowspan="1"><p>173,388</p><p>POU:</p><p>3,523 (2.0%)</p></td><td align="left" colspan="1" rowspan="1"><p>Age 2&#8211;6:</p><p>Ethnicity Asian (vs European):</p><p>aOR&#8201;=&#8201;0.24; 95% CI 0.06&#8211;0.97,</p><p>African American: aOR&#8201;=&#8201;1.50; 95% CI 1.00&#8211;2.20</p><p>Age 6&#8211;12:</p><p>Asian: aOR&#8201;=&#8201;0.33; 95% CI 0.12&#8211;0.90</p><p>Age 12&#8211;18:</p><p>Male: aOR&#8201;=&#8201;0.82; 95% CI 0.75&#8211;0.89</p><p>Asian: aOR&#8201;=&#8201;0.51; 95% CI 0.34&#8211;0.77</p><p>Mood disorder: aOR&#8201;=&#8201;1.4; 95% CI 1.2&#8211;1.6</p><p>SUD: aOR&#8201;=&#8201;1.30; 95% CI 1.00&#8211;1.70 Chronic Pain: aOR&#8201;=&#8201;1.40; 95% CI 1.20&#8211;1.60</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Brown et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR33">33</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions</p><p>Opioid exposure 6&#160;months prior</p><p>Palliation within 6&#160;months after surgery</p><p>Subsequent anesthesia 6&#160;months after surgery</p><p>Preoperative metastatic disease</p></td><td align="left" colspan="1" rowspan="1"><p>January 2004 to December 2016</p><p>Medico-administrative (Optumlab)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Cardiac</p></td><td align="left" colspan="1" rowspan="1"><p>35,817</p><p>POU:</p><p>3,430 (9.6%)</p></td><td align="left" colspan="1" rowspan="1"><p>Men: aOR&#8201;=&#8201;0.87; 95% CI 0.79&#8211;0.97</p><p>Income 100&#160;K (ref&#8201;&lt;&#8201;40&#160;k): aOR&#8201;=&#8201;0.87; 95% CI 0.77&#8211;0.99</p><p>Rheumatoid arthritis: aOR&#8201;=&#8201;1.57; 95% CI 1.25&#8211;1.96 Chronic pain: aOR&#8201;=&#8201;2.73; 95% CI 2.10&#8211;3.56</p><p>Alcohol misuse: aOR&#8201;=&#8201;1.56; 95% CI 1.23&#8211;2.00</p><p>Muscle relaxant use: aOR&#8201;=&#8201;1.74; 95% CI 1.51&#8211;2.02 Benzodiazepine use: aOR&#8201;=&#8201;1.71; 95% CI 1.52&#8211;1.91</p><p>Length of stay: aOR&#8201;=&#8201;1.03; 95% CI 1.01&#8211;1.04</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Clement et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR34">34</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: Adult</p><p>Exclusions</p><p>Opioid exposure 365 to 31&#160;days prior</p><p>Died in hospital</p><p>Discharged to hospice</p><p>Underwent concomitant coronary artery bypass grafting</p><p>Subsequent surgery within 180&#160;days</p></td><td align="left" colspan="1" rowspan="1"><p>2014 to 2016</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Heart valve</p></td><td align="left" colspan="1" rowspan="1"><p>3,404</p><p>POU:</p><p>188 (5.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Perioperative OME increase:</p><p>aOR&#8201;=&#8201;1.01; 95% CI 1.01&#8211;1.01</p><p>1% increase for every 10&#160;mg OME prescribed</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Clement et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR35">35</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: Adult</p><p>Exclusions</p><p>Opioid exposure 365 to 31&#160;days prior</p><p>Died in hospital</p><p>Discharged to hospice</p><p>Subsequent major surgery within 180&#160;days</p><p>Descending and thoracoabdominal aortic repairs</p></td><td align="left" colspan="1" rowspan="1"><p>January 2012 to December 2017</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Open thoracic aortic</p></td><td align="left" colspan="1" rowspan="1"><p>3,204</p><p>POU:</p><p>169 (5.3%)</p></td><td align="left" colspan="1" rowspan="1"><p>Perioperative OME increase:</p><p>aOR&#8201;=&#8201;1.01; 95% CI 1.00&#8211;1.01</p><p>1% increase for every 10&#160;mg OME prescribed</p><p>nicotine use: aOR&#8201;=&#8201;2.09; 95% CI 1.35&#8211;3.25</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Clement et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR36">36</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age: Adult</p><p>Exclusions</p><p>Opioid exposure 365 to 31&#160;days prior</p><p>Died in hospital</p><p>Discharged to hospice</p><p>Subsequent surgery within 180&#160;days</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p></td><td align="left" colspan="1" rowspan="1"><p>2014 to 2016</p><p>Medico-administrative (MarketScan)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Coronary bypass</p></td><td align="left" colspan="1" rowspan="1"><p>7,292</p><p>POU:</p><p>590 (8.1%)</p></td><td align="left" colspan="1" rowspan="1"><p>Female: aOR&#8201;=&#8201;1.30; 95% CI 1.05&#8211;1.61</p><p>Anxiety: aOR&#8201;=&#8201;1.40; 95% CI 1.09&#8211;1.81</p><p>tobacco use: aOR&#8201;=&#8201;1.34; 95% CI 1.08&#8211;1.65</p><p>Substance misuse: aOR&#8201;=&#8201;1.99; 95% CI 1.08&#8211;1.65</p><p>Length of stay: aOR&#8201;=&#8201;1.02; 95% CI 0.99&#8211;1.05</p><p>Perioperative OME increase:</p><p>aOR&#8201;=&#8201;1.02; 95% CI 1.01&#8211;1.02</p><p>2% increase for every 10&#160;mg OME prescribed</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Santosa et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR37">37</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;65</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Additional procedure 180&#160;days after</p></td><td align="left" colspan="1" rowspan="1"><p>January 2009 to June 2015</p><p>Medico-administrative (Medicare)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before and 14&#160;days after surgery, additional dispensing of any opioids 90 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>13 selected procedures</p></td><td align="left" colspan="1" rowspan="1"><p>81,839</p><p>POU:</p><p>8,021 (9.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Charlson comorbidity&#8201;&#8805;&#8201;5 (vs 0):</p><p>aOR&#8201;=&#8201;1.71; 95% CI 1.58&#8211;1.84</p><p>Mood disorders: aOR&#8201;=&#8201;1.16; 95% CI 1.09&#8211;1.24)</p><p>Suicide: aOR&#8201;=&#8201;1.60; 95% CI 1.05&#8211;2.44</p><p>Alcohol misuse: aOR&#8201;=&#8201;1.38; 95% CI 1.20&#8211;1.59</p><p>Back Pain: aOR&#8201;=&#8201;1.16; 95% CI 1.07&#8211;1.27</p><p>Total Perioperative OME (&gt;&#8201;300&#160;mg):</p><p>aOR&#8201;=&#8201;1.44; 95% CI 1.37&#8211;1.52</p><p>Hypnotic use: aOR&#8201;=&#8201;1.24; 95% CI 1.14&#8211;1.35</p><p>Benzodiazepine use: aOR&#8201;=&#8201;1.24; 95% CI 1.14&#8211;1.35</p><p>African American (vs Caucasian)</p><p>aOR&#8201;=&#8201;1.23; 95% CI 1.12&#8211;1.36</p><p>Long-acting opioids on discharge:</p><p>aOR&#8201;=&#8201;2.87; 95% CI 2.18, 3.76</p><p>Co-prescribed benzodiazepine on discharge:</p><p>aOR&#8201;=&#8201;4.83; 95% CI 4.08&#8211;5.71</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Delaney et al</p><p>2020</p><p>United States [<xref ref-type="bibr" rid="CR38">38</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;65</p><p>Exclusions</p><p>Opioid exposure 11&#160;months prior</p><p>Discharged to facility (other than home)</p><p>Length of stay&#8201;&gt;&#8201;30&#160;days</p><p>Additional anaesthetic code 180&#160;days after</p></td><td align="left" colspan="1" rowspan="1"><p>January 2013 to June 2016</p><p>Medico-administrative (Medicare)</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 30&#160;days before admission and 3&#160;days after discharge, additional dispensing of any opioids 91 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>Orthopaedic</p></td><td align="left" colspan="1" rowspan="1"><p>1,403</p><p>POU:</p><p>97 (6.9%)</p></td><td align="left" colspan="1" rowspan="1"><p>Total OME on discharge 3rd quartile, 497 OME (vs 1st quartile):</p><p>aOR&#8201;=&#8201;2.91; 95% CI 1.53&#8211;5.51</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Beyene et al</p><p>2022</p><p>New Zealand [<xref ref-type="bibr" rid="CR39">39</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>Retrospective</p><p>Age:&#8201;&#8805;&#8201;18</p><p>Exclusions</p><p>Opioid exposure 90&#160;days prior</p><p>Subsequent surgery or trauma 180&#160;days after</p><p>Discharged to facility</p></td><td align="left" colspan="1" rowspan="1"><p>January to December 2019</p><p>Institutional data</p></td><td align="left" colspan="1" rowspan="1">Opioid dispensed 7 after discharge, additional dispensing of any opioids 91 to 180&#160;days</td><td align="left" colspan="1" rowspan="1"><p>Surgery</p><p>General surgery</p></td><td align="left" colspan="1" rowspan="1"><p>401</p><p>POU:</p><p>38 (9.5%)</p></td><td align="left" colspan="1" rowspan="1"><p>Female: aOR&#8201;=&#8201;2.29; 95% CI 1.07&#8211;4.90</p><p>Length of stay&#8201;&gt;&#8201;24&#160;h: aOR&#8201;=&#8201;3.07; 95% CI 1.30&#8211;7.21 Perioperative OME&#8201;&gt;&#8201;100: aOR&#8201;=&#8201;3.04; 95% CI 1.25&#8211;7.40</p><p>Surgical severity:</p><p>Category 3 severity (vs 1): aOR&#8201;=&#8201;0.17; 95% CI 0.01&#8211;0.53</p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic toggle="yes">K</italic> 1,000 in US dollar currency e.g. $US70,000</p><p><sup>b</sup><italic toggle="yes">OME</italic> Oral morphine equivalent</p><p><sup>c</sup><italic toggle="yes">SUD</italic> Substance use disorder</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>Incidence of POU</title><p id="Par32">In the 19 surgical studies with patients 18&#160;years and over, the reported incidence of POU among opioid na&#239;ve users varied between 3.9% (<italic toggle="yes">n</italic>&#8201;=&#8201;153) to 14.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;424) [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. However, among the 19 studies, two included predominantly younger patients with lower incidences of POU &#8211;<italic toggle="yes">Harbaugh </italic>et al. included patients aged between 13 to 21 [<xref ref-type="bibr" rid="CR21">21</xref>], whilst <italic toggle="yes">Bennet </italic>et al. included patients aged between 8 to 25 [<xref ref-type="bibr" rid="CR22">22</xref>]. The incidence of POU was similar in these two studies at 4.8% (<italic toggle="yes">n</italic>&#8201;=&#8201;4,267) and 4.4% (<italic toggle="yes">n</italic>&#8201;=&#8201;90) respectively [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In the single surgical study with patients under 18, the incidence of POU was found to be 2.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;3,523) [<xref ref-type="bibr" rid="CR32">32</xref>]. In surgical studies that included a range of surgical specialties and in patients 18&#160;years and over, the incidence of POU was 3.9% (<italic toggle="yes">n</italic>&#8201;=&#8201;153) to 10.2% (<italic toggle="yes">n</italic>&#8201;=&#8201;93,159) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. In cardiac surgery amongst patient 18&#160;years and over, the incidence of POU was 5.2% (<italic toggle="yes">n</italic>&#8201;=&#8201;169) to 12.8% (<italic toggle="yes">n</italic>&#8201;=&#8201;3,153) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>]. The surgical specialty (and incidence of POU) in other studies with patients 18&#160;years and over were in cancer-related surgery with curative intent (10.0% [<italic toggle="yes">n</italic>&#8201;=&#8201;4,159] to 14.0% [<italic toggle="yes">n</italic>&#8201;=&#8201;424]) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], urological (6.2% [<italic toggle="yes">n</italic>&#8201;=&#8201;2,399]) [<xref ref-type="bibr" rid="CR27">27</xref>], orthopaedic (6.9% [<italic toggle="yes">n</italic>&#8201;=&#8201;97] to 8.3% [<italic toggle="yes">n</italic>&#8201;=&#8201;8,686]) [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], gynaecology (6.8% [<italic toggle="yes">n</italic>&#8201;=&#8201;29,643]) [<xref ref-type="bibr" rid="CR29">29</xref>], and general surgery (9.5% [<italic toggle="yes">n</italic>&#8201;=&#8201;38]) [<xref ref-type="bibr" rid="CR39">39</xref>]. In the two trauma studies, the incidence of POU was between 8.1% (<italic toggle="yes">n</italic>&#8201;=&#8201;1,061) and 10.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;6,272) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec11"><title>Sociodemographic risk factors of POU</title><p id="Par33">Age as a potential risk factor of POU was included in the final analysis for 19 of the 20 surgical studies. However, age was not consistently identified as a significant risk factor. Of these, 63.2% (12/19) surgical studies found age to be a significant risk factor for POU. Over half (7/12) of the studies found that patients of older age had high risk of POU [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Comparison of effect size between studies was difficult given each study had arbitrarily defined their age groups and used different age groups as the reference. One exception was in a gynaecology study where younger patients aged 18 to 29&#160;years were reported to have the highest risk of becoming persistent opioid users compared to other age groups (aOR&#8201;=&#8201;1.22; 95% CI 1.17&#8211;1.29, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR29">29</xref>]. Another study conducted in orthopaedic patients found mixed results with respect to age, when compared to age 50&#8211;59, age 18&#8211;29 (aOR&#8201;=&#8201;0.68; 95% CI 0.61&#8211;0.76, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and over 70 (aOR&#8201;=&#8201;0.90; 95% CI 0.81&#8211;0.99, <italic toggle="yes">P</italic>&#8201;=&#8201;0.035) both had decreased odds of POU [<xref ref-type="bibr" rid="CR28">28</xref>]. In the trauma studies, all studies included age as a risk factor but only one study found age to have a statistically significant association with POU [<xref ref-type="bibr" rid="CR18">18</xref>]. The study found those aged over 65&#160;years compared to 18 to 34&#160;years had lower odds of becoming a persistent opioid user (aOR&#8201;=&#8201;0.80; 95% CI 0.70&#8211;0.90, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001) [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par34">A total of 90.0% (18/20) of surgical studies included sex as a risk factor for POU, half (9/18) of these studies found sex was a significant risk factor. Of these, 88.9% (8/9) of the studies found that females were at higher odds of developing POU with aORs between 1.14 and 2.29 [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Both trauma studies found females to have a small increase in odds of developing POU with aOR of 1.10 and 1.16 respectively [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par35">A total of 35% (7/20) of the surgical studies included ethnicity as a risk factor for POU, and 42.9% (3/7) of those studies found significant differences in developing POU between ethnicities. When compared to Europeans, African Americans were at higher odds of becoming POU in all three studies aOR between 1.23 and 1.50 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Only one trauma study included ethnicity as a risk factor but it was not found to be statistically significant [<xref ref-type="bibr" rid="CR31">31</xref>]. Over one third (7/20) of surgical studies that included annual income as a risk factor of POU, 42.9% (3/7) surgical studies found that income was a statistically significant variable, and annual income higher than $USD 70,000 was negatively associated with POU with aOR between 0.75 and 0.90 [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, both trauma studies found annual income greater than $USD 70,000 was associated with significantly reduced risk of POU aOR of 0.70 and 0.73 respectively [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec12"><title>Baseline comorbidities</title><p id="Par36">Over a third (7/20) of surgical studies that included a comorbidity index such as Charlson or Elixhauser, as a measure of a patient&#8217;s overall comorbidity burden, and as a risk factor of POU; 85.7% (6/7) studies reported that a greater comorbidity burden was positively associated with POU, whilst one did not find that overall comorbidity burden was a significant risk factor [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Out of the studies that found a greater comorbidity burden was positively associated with POU, 83.3% (5/6) of studies used the Charlson index as a measure of overall comorbidity burden; however different approaches on how comorbidity was measured differed across studies. In the one surgical study using the Elixhauser comorbidity index, an increased score (indicating increased comorbidity burden) was associated with a 2.0% increase in the risk of POU per additional point on the index (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR20">20</xref>]. Similarly, both trauma studies reported that greater comorbidity burden was also associated with increased odds of POU. However, the two studies were not comparable as they used different indices to measure overall comorbidity burden; <italic toggle="yes">Johnson </italic>et al<italic toggle="yes">.</italic> used the Elixhauser index and <italic toggle="yes">Gossett </italic>et al<italic toggle="yes">.</italic> used the Charlson index [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par37">Baseline diagnosis of mental health and pain-related disorders were the most common comorbidities included in the analysis for POU in both surgical and trauma patients. Of the 20 surgical studies included, 70.0% (14/20) of the studies had at least one mental health disorder [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref>] and half (10/20) of the surgical studies included at least one pain-related disorder [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. The most commonly reported mental health disorder was previous substance use disorder (SUD) from 57.1% (8/14) of the surgical studies, which all had positive associations with POU; aOR was between 1.30 and 1.99 [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Less than half (4/10) of surgical studies, that included any pain-related disorder found back pain was the most consistently positive significant predictor for POU; aOR between 1.09 and 1.27 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par38">The two trauma studies included both mental health and pain-related disorders [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. SUD was also the most commonly reported risk factor related to mental health disorder among trauma studies, but only one study found it to be a significant risk factor of POU (aOR&#8201;=&#8201;1.33; 95% CI 1.01&#8211;1.75, <italic toggle="yes">P</italic>&#8201;=&#8201;0.040) [<xref ref-type="bibr" rid="CR31">31</xref>]. Both trauma studies also included baseline pain disorders, <italic toggle="yes">Johnson </italic>et al<italic toggle="yes">.</italic> found it was a significant risk factor [<xref ref-type="bibr" rid="CR18">18</xref>] and <italic toggle="yes">Gossett </italic>et al<italic toggle="yes">.</italic> found it was negatively associated with POU (aOR&#8201;=&#8201;0.56; 95% CI 0.43&#8211;0.72, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR31">31</xref>]. Only arthritis was included under the category of pain disorders in the study by <italic toggle="yes">Gossett </italic>et al. [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec13"><title>Baseline medication use</title><p id="Par39">Medication use prior to hospital admission did not commonly feature as an independent risk factor of POU in either surgery or trauma studies examined. Only 10.0% (2/20) of surgical studies examined baseline medication use, and the studies found hypnotics such as benzodiazepines increased the odds of POU in both studies with aOR of 1.24 and 1.71 [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. No trauma studies included any baseline medication use as a risk factor of POU.</p></sec><sec id="Sec14"><title>Inpatient variables</title><p id="Par40">Operation type was commonly included as a risk factor for POU in surgical studies, but given the heterogeneity in how different operations were defined between studies, it was not possible to group these for comparison. Hospital length of stay (LOS) was included as a risk factor in over a third (7/20) of surgical studies [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], and 71.4% (5/7) studies found increasing LOS to be a positive risk factor of POU [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Four studies defined this variable similarly as increased in odds per each additional day of LOS and this was reflected in their closely aligned effect size (aOR between 1.02 to 1.05) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The study by <italic toggle="yes">Brescia </italic>et al<italic toggle="yes">.</italic> defines LOS as a dichotomous variable of more than five days (vs less than five days) and found aOR&#8201;=&#8201;1.30; 95% CI 1.04&#8211;1.63, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001 [<xref ref-type="bibr" rid="CR23">23</xref>]. LOS was not included as a risk factor for any trauma studies.</p></sec><sec id="Sec15"><title>Opioid prescribing practices after the surgical or trauma event</title><p id="Par41">Of the surgical studies included 65.0% (13/20) had included any opioid prescribing practices after surgery as a risk factor for POU. This was analysed by considering the total amount of opioid dose on the discharge prescription, converting this to an oral morphine equivalent (OME)- in milligrams, and consider the supply during the perioperative period. This was a risk factor that was included in all 13 studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR39">39</xref>]. All studies found that increasing dosages of opioids prescribed during the perioperative period were associated with increased odds of POU. However, there were large variations between studies on how the POU variable was defined and analysed, making comparisons between studies difficult. One trauma study by <italic toggle="yes">Gossett </italic>et al<italic toggle="yes">.</italic> found that patients who were prescribed larger quantities of opioids (more than 650&#160;mg in OME) after discharge were associated with increased odds of becoming a persistent opioid user (aOR&#8201;=&#8201;1.56; 95% CI 1.34&#8211;1.82) [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec16"><title>Risk of <italic toggle="yes">bias</italic> assessment</title><p id="Par42">The overall risk of bias across all studies were low (21 out of 22 studies), with only one surgical study being classified being at high risk of bias [<xref ref-type="bibr" rid="CR26">26</xref>]. In terms of selection bias, all studies scored between three to four stars (maximum being four stars). In the comparability category, only one surgical study scored the maximum two stars as it required the inclusion of marital status, and another surgical study scored zero stars as no confounders were included for the analysis of risk factors related to POU [<xref ref-type="bibr" rid="CR26">26</xref>]. Lastly, in the outcome category, 19 out of the 22 studies received the maximum allocated three stars and three out of 22 receiving two stars. See Table&#160;<xref rid="Tab2" ref-type="table">2</xref> for scoring per item for included studies.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Newcastle&#8211;Ottawa scale ratings for included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="left" colspan="4" rowspan="1">Selection</th><th align="left" colspan="1" rowspan="1">Comparability</th><th align="left" colspan="3" rowspan="1">Outcome</th><th align="left" rowspan="2" colspan="1">Total score and quality</th></tr><tr><th align="left" colspan="1" rowspan="1">Representativeness of exposed cohort (one star)</th><th align="left" colspan="1" rowspan="1">Selection of non-exposed cohort (one star)</th><th align="left" colspan="1" rowspan="1">Ascertainment of exposure (one start)</th><th align="left" colspan="1" rowspan="1">Outcome of interest does not present at start of star (one star)</th><th align="left" colspan="1" rowspan="1">One or two stars</th><th align="left" colspan="1" rowspan="1">Assessment of outcome (one star)</th><th align="left" colspan="1" rowspan="1">Length of follow up adequate for outcome (one star)</th><th align="left" colspan="1" rowspan="1">Adequacy of follow up (one star</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Bennet et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Berger et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Beyene et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Bicket et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">**</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Brescia et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Brescia et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Brown et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Brummet et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Clement et al. [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Clement et al. [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Clement et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Delaney et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Gil et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Gossett et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Harbaugh et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Johnson et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Lee et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Roughead et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6 Poor</td></tr><tr><td align="left" colspan="1" rowspan="1">Santosa et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiels et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Ward et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr><tr><td align="left" colspan="1" rowspan="1">Wright et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">*</td><td align="left" colspan="1" rowspan="1">8 Good</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par43">This review was a systematic review of the current literature on the topic of POU that has synthesised evidence in patients after surgery or trauma, without restriction to specific surgical specialties and inclusion of only opioid-na&#239;ve patients. The findings of this review align closely with other systematic reviews conducted in the surgical and trauma space [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, the review is the first to systematically synthesise and compare findings between opioid-na&#239;ve surgical and trauma patients to highlight differences in the incidence of POU and risk factors in the current literature. Being able to systematically review these risk factors provides an important foundation to inform future research to reduce POU. A total of 22 studies were included, comprising of 20 surgical studies and two trauma studies. The quality of the studies was generally of good quality; however, most studies were of U.S origin and used medico-administrative data. The review also highlights the need for further research related to opioid use and opioid-related adverse events in countries outside of North America. Overall, there were large differences in the incidence of POU observed across studies regardless of them being either surgical or trauma cohorts. In the surgical cohort, we observed that studies with an adult population had relatively higher incidences of POU than those with mostly paediatric and young adult populations. This may reflect prescribing practice, where opioids are used more conservatively in younger patients, as younger patients may have more potential to develop addiction behaviours [<xref ref-type="bibr" rid="CR40">40</xref>], and dosing may be more difficult [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par44">Among the reported sociodemographic variables, no variables had consistent association with POU in surgical or trauma cohorts. However, in baseline comorbidities, there was a close alignment of findings. Among the seven surgical studies that included a comorbidity index, 85.7% (6/7) studies found that increasing comorbidity burden increased the odds of POU. Similar findings were also reported in both trauma studies. This was unsurprising, given that higher comorbidity burdens have also been shown to correlate with worse surgical and trauma outcomes [<xref ref-type="bibr" rid="CR42">42</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. These outcomes may result in hospital readmission and surgical complications, increasing the likelihood of prolonged opioid exposure. SUD was associated with increased POU in over half of the surgical studies that included a mental health disorder. Comparatively, in trauma studies, half of the studies that included mental health disorder as a risk factor found SUD was a significant risk factor [<xref ref-type="bibr" rid="CR18">18</xref>]. There are complex dynamics in pain management and SUD, and it has been shown patients with SUD are less likely to receive effective pain management in both emergency and postoperative settings as there are concerns for misuse [<xref ref-type="bibr" rid="CR46">46</xref>]. Furthermore, the co-existence of addiction and pain may act synergistically to re-enforce symptoms of either component, resulting in a vicious cycle of using other substances to manage pain and vice versa, i.e. opioids for addiction [<xref ref-type="bibr" rid="CR47">47</xref>]. Both complications will likely result in poor pain control and increased risks of POU.</p><p id="Par45">Benzodiazepines and increased risk of POU were unique to surgical studies as no trauma studies included this variable as a risk factor, which represents a gap for future research. The indications for benzodiazepines are broad, including anticonvulsant, anxiolytic, sedative, and muscle relaxant. Patients taking concomitant benzodiazepine at the time of surgery may indicate a history of anxiety, which has also been shown to increase odds of POU [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Patients with anxiety may have higher chances of catastrophising pain, which may result in increased opioid need and chronic pain post-surgery [<xref ref-type="bibr" rid="CR48">48</xref>]. It should also be noted that the co-prescribing of benzodiazepine and opioids is not recommended, as it may increase the risk of overdose via suppressing airways and impairing cognitive functions [<xref ref-type="bibr" rid="CR49">49</xref>]. Of the surgical studies, 71.4% (5/7) of the studies found that longer LOS was associated with increased odds of POU, and this was consistent regardless of other indicators of operation severity or invasiveness (open vs laparoscopic) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. As LOS is a proxy for hospital resource use, a higher LOS may indicate postoperative complications such as a need for additional surgery or admission to intensive care [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Thus, greater LOS may result in greater analgesic need and increased complexity in pain management. Higher opioid amount during the perioperative and post-trauma period, as indicated via OME, was consistently found to be a significant risk factor of POU. The OME prescribed in this period may represent a risk for greater ongoing analgesia need but also reflect an over-supply of opioids on discharge, which we cannot determine from this review.</p><p id="Par46">This review has several limitations. The initial search excluded conference proceedings due to limited information that can be captured in the proceedings. In our piloted searches the definition of POU and opioid-na&#239;ve status of patients were not detailed enough to be assessed for inclusion. Some studies may be missed due to the exclusion of conference proceedings, which may alter our reporting of the incidence of POU and effect size of risk factors. We considered the study to be involving opioid-na&#239;ve patients if the study mentioned that its analysis was restricted to opioid-na&#239;ve patients, but this may not be representative of true opioid-naivety. The studies mostly considered patients to be opioid na&#239;ve based on the absence of recent pharmacy claims for opioid dispensing up to 12&#160;months prior to the event. However, patients may be included in the study if they had been dispensed opioids prior to the 12&#160;months look-back period and may have had a diagnosis of SUD (including opioids). Only two studies in this review also excluded patients with a previous diagnosis of opioid-related SUD or having been on treatment for opioid dependence, in addition to the absence of recent opioid dispensing [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Thus, the inclusion of patients with a previous diagnosis of opioid-related SUD in some studies may overestimate the prevalence of POU. The POU definition used in our review was specific so that the studies included could be comparable, but as the definition was narrow it may have excluded potentially relevant studies. Recent meta-analysis on POU definitions found the incidence of POU can vary up to two-fold depending on the definition used [<xref ref-type="bibr" rid="CR3">3</xref>]. Thus, given the already significant heterogeneity in study design, broader POU definitions may give rise to further incongruity of findings across studies [<xref ref-type="bibr" rid="CR3">3</xref>]. The nature of studies included also had limitations, as studies were mostly of US origin using medico-administrative data. This may not reflect the health system and healthcare utilisation patterns of other countries. The medico-administrative studies used either prescribing or pharmacy dispensing data as a proxy for the actual consumption of opioids, which may not represent the actual use of opioids. The studies included also did not provide any indications as to why patients continued to use opioids beyond 90&#160;days as it may be clinically indicated in some patients with complex postoperative recovery. Finally, due to the significant heterogeneity in study design, cohort selection and reporting of risk factors, a meta-analysis could not be performed. Whilst we found that the quality of the studies was mostly good but there was some evidence of bias in all studies particularly relating to comparability. Outcomes related to POU were beyond the scope of this review but as there has been growing interest in evaluating outcomes related to POU as a long-term prognostic marker of poor outcomes after surgery and trauma, this is an area for further research. Recent studies have reported that POU may be associated with increased risk of mortality and morbidity [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec18"><title>Conclusion</title><p id="Par47">This was the first review that we are aware of to examine the incidence of POU among opioid na&#239;ve patients after surgery or trauma. The review found that a significant proportion of opioid-na&#239;ve patients 18 and over following exposure to opioids after hospitalisation for surgery or trauma, may develop POU. Our findings suggest that there may be risk factors that were consistently and independently associated with increased odds of POU, irrespective of surgery or trauma. These risk factors included having a history of mental health disorders, chronic pain disorders, higher comorbidity burden, baseline hypnotic use, increased LOS, or being prescribed higher doses of opioids during the perioperative and postoperative and post-trauma period. These risk factors may be considered by prescribers to assess the risk of POU after surgery or trauma, when continuing opioids after hospitalisation. The overall quality of studies included was good, and the review also found several gaps in the literature related to trauma patients, which represents opportunities for future research to explore all relevant patient and clinical variables as risk factors for POU.</p></sec><sec sec-type="supplementary-material"><sec id="Sec20"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12893_2024_2494_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>J.G. was involved in the conception of the paper, undertaking literature review, analysis of the literature, manuscript write-up and review of the submission for publication. P.J. was involved in the conception of the paper, the development of the research question and the review of the manuscript.A.H.Y.C. was involved in the conception of the paper, development of the research question, and secondary screening of studies for inclusion, appraisal of selected studies and review of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by the Auckland Academic Health Alliance (AAHA) no. 8753 and the NZ HRC no. 21/056.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p> The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par48">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par49">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par50">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kent</surname><given-names>ML</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>RW</given-names></name><name name-style="western"><surname>Oderda</surname><given-names>GM</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>DB</given-names></name><name name-style="western"><surname>Sun</surname><given-names>E</given-names></name><name name-style="western"><surname>Mythen</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>TE</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gan</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>JKM</given-names></name><etal/></person-group><article-title>American Society for Enhanced Recovery and Perioperative Quality Initiative-4 joint consensus statement on persistent postoperative opioid use: definition, incidence, risk factors, and health care system initiatives</article-title><source>Anesth Analg</source><year>2019</year><volume>129</volume><issue>2</issue><fpage>543</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000003941</pub-id><pub-id pub-id-type="pmid">30897590</pub-id><pub-id pub-id-type="pmcid">PMC6640123</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schug</surname><given-names>SA</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>GM</given-names></name><name name-style="western"><surname>Scott</surname><given-names>DA</given-names></name><name name-style="western"><surname>Halliwell</surname><given-names>R</given-names></name><name name-style="western"><surname>Trinca</surname><given-names>J</given-names></name></person-group><article-title>Acute pain management: scientific evidence, fourth edition 2015.</article-title><source>Med J Aust</source><year>2016</year><volume>204</volume><issue>8</issue><fpage>315</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.5694/mja16.00133</pub-id><pub-id pub-id-type="pmid">27125806</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jivraj</surname><given-names>NK</given-names></name><name name-style="western"><surname>Raghavji</surname><given-names>F</given-names></name><name name-style="western"><surname>Bethell</surname><given-names>J</given-names></name><name name-style="western"><surname>Wijeysundera</surname><given-names>DN</given-names></name><name name-style="western"><surname>Ladha</surname><given-names>KS</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>BT</given-names></name><name name-style="western"><surname>Neuman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Wunsch</surname><given-names>H</given-names></name></person-group><article-title>Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study</article-title><source>Anesthesiology</source><year>2020</year><volume>132</volume><issue>6</issue><fpage>1528</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000003265</pub-id><pub-id pub-id-type="pmid">32243330</pub-id><pub-id pub-id-type="pmcid">PMC8202398</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schug</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lavand&#700;homme</surname><given-names>P</given-names></name><name name-style="western"><surname>Barke</surname><given-names>A</given-names></name><name name-style="western"><surname>Korwisi</surname><given-names>B</given-names></name><name name-style="western"><surname>Rief</surname><given-names>W</given-names></name><name name-style="western"><surname>Treede</surname><given-names>RD</given-names></name></person-group><article-title>The IASP classification of chronic pain for ICD-11: chronic postsurgical or posttraumatic pain</article-title><source>Pain</source><year>2019</year><volume>160</volume><issue>1</issue><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001413</pub-id><pub-id pub-id-type="pmid">30586070</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pag&#233;</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kudrina</surname><given-names>I</given-names></name><name name-style="western"><surname>Zomahoun</surname><given-names>HTV</given-names></name><name name-style="western"><surname>Croteau</surname><given-names>J</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>D</given-names></name><name name-style="western"><surname>Ngangue</surname><given-names>P</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E</given-names></name><name name-style="western"><surname>Fortier</surname><given-names>M</given-names></name><name name-style="western"><surname>Boisvert</surname><given-names>EE</given-names></name><name name-style="western"><surname>Beaulieu</surname><given-names>P</given-names></name><etal/></person-group><article-title>A systematic review of the relative frequency and risk factors for prolonged opioid prescription following surgery and trauma among adults</article-title><source>Ann Surg</source><year>2020</year><volume>271</volume><issue>5</issue><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000003403</pub-id><pub-id pub-id-type="pmid">31188226</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawal</surname><given-names>OD</given-names></name><name name-style="western"><surname>Gold</surname><given-names>J</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Bavry</surname><given-names>E</given-names></name><name name-style="western"><surname>Hume</surname><given-names>AL</given-names></name><name name-style="western"><surname>Lewkowitz</surname><given-names>AK</given-names></name><name name-style="western"><surname>Brothers</surname><given-names>T</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name></person-group><article-title>Rate and risk factors associated with prolonged opioid use after surgery: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>6</issue><fpage>e207367</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.7367</pub-id><pub-id pub-id-type="pmid">32584407</pub-id><pub-id pub-id-type="pmcid">PMC7317603</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riva</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Noor</surname><given-names>ST</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ashoorion</surname><given-names>V</given-names></name><name name-style="western"><surname>Foroutan</surname><given-names>F</given-names></name><name name-style="western"><surname>Sadeghirad</surname><given-names>B</given-names></name><name name-style="western"><surname>Couban</surname><given-names>R</given-names></name><name name-style="western"><surname>Busse</surname><given-names>JW</given-names></name></person-group><article-title>Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults</article-title><source>Ann Intern Med</source><year>2020</year><volume>173</volume><issue>9</issue><fpage>721</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.7326/M19-3600</pub-id><pub-id pub-id-type="pmid">32805130</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>TM</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>J</given-names></name><name name-style="western"><surname>Vetor</surname><given-names>A</given-names></name><name name-style="western"><surname>Mongalo</surname><given-names>A</given-names></name><name name-style="western"><surname>Adams</surname><given-names>Z</given-names></name><name name-style="western"><surname>Rouse</surname><given-names>T</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>A</given-names></name></person-group><article-title>Long-term prescription opioid utilization, substance use disorders, and opioid overdoses after adolescent trauma</article-title><source>J Trauma Acute Care Surg</source><year>2019</year><volume>87</volume><issue>4</issue><fpage>836</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1097/TA.0000000000002261</pub-id><pub-id pub-id-type="pmid">30889139</pub-id><pub-id pub-id-type="pmcid">PMC6745292</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braden</surname><given-names>JB</given-names></name><name name-style="western"><surname>Russo</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>MY</given-names></name><name name-style="western"><surname>Edlund</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>BC</given-names></name><name name-style="western"><surname>DeVries</surname><given-names>A</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>MD</given-names></name></person-group><article-title>Emergency department visits among recipients of chronic opioid therapy</article-title><source>Arch Intern Med</source><year>2010</year><volume>170</volume><issue>16</issue><fpage>1425</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2010.273</pub-id><pub-id pub-id-type="pmid">20837827</pub-id><pub-id pub-id-type="pmcid">PMC3715046</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elkbuli</surname><given-names>AMDMPH</given-names></name><name name-style="western"><surname>Narvel</surname><given-names>RI</given-names></name><name name-style="western"><surname>Boneva</surname><given-names>DMD</given-names></name><name name-style="western"><surname>McKenney</surname><given-names>MMDMBA</given-names></name></person-group><article-title>The impact of chronic opioid use on trauma outcomes</article-title><source>Am Surg </source><year>2020</year><volume>86</volume><issue>1</issue><fpage>E35</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1177/000313482008600119</pub-id><pub-id pub-id-type="pmid">32077433</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Santosa KB, Priest CR, Oliver JD, Kenney B, Bicket MC, Brummett CM, Waljee JF. Long-Term Health Outcomes of New Persistent Opioid Use after Surgery among Medicare Beneficiaries. Ann Surg. 2023;278(3):e491&#8211;5. 10.1097/SLA.0000000000005752.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000005752</pub-id><pub-id pub-id-type="pmid">36375090</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenhalgh</surname><given-names>T</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>R</given-names></name></person-group><article-title>Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources</article-title><source>BMJ</source><year>2005</year><volume>331</volume><issue>7524</issue><fpage>1064</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1136/bmj.38636.593461.68</pub-id><pub-id pub-id-type="pmid">16230312</pub-id><pub-id pub-id-type="pmcid">PMC1283190</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouzzani</surname><given-names>M</given-names></name><name name-style="western"><surname>Hammady</surname><given-names>H</given-names></name><name name-style="western"><surname>Fedorowicz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Elmagarmid</surname><given-names>A</given-names></name></person-group><article-title>Rayyan&#8212;a web and mobile app for systematic reviews</article-title><source>Syst Rev</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>210</fpage><pub-id pub-id-type="doi">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmid">27919275</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Wells G, Shea B, O&#8217;Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link>.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ren</surname><given-names>P</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D</given-names></name></person-group><article-title>The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews/meta-analysis</article-title><source>J Evid Based Med</source><year>2021</year><volume>14</volume><issue>2</issue><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1111/jebm.12427</pub-id><pub-id pub-id-type="pmid">34002466</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suckling</surname><given-names>B</given-names></name><name name-style="western"><surname>Pattullo</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>James</surname><given-names>P</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>P</given-names></name><name name-style="western"><surname>Patanwala</surname><given-names>A</given-names></name><name name-style="western"><surname>Penm</surname><given-names>J</given-names></name></person-group><article-title>Persistent opioid use after hospital discharge in Australia: a systematic review</article-title><source>Aust Health Rev</source><year>2022</year><volume>46</volume><issue>3</issue><fpage>367</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1071/AH21353</pub-id><pub-id pub-id-type="pmid">35545810</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>SP</given-names></name><name name-style="western"><surname>Chung</surname><given-names>KC</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><name name-style="western"><surname>Shauver</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Engelsbe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>C</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name></person-group><article-title>Risk of Prolonged Opioid Use Among Opioid-Na&#239;ve Patients Following Common Hand Surgery Procedures</article-title><source>J Hand Surg Am</source><year>2016</year><volume>41</volume><issue>10</issue><fpage>947</fpage><lpage>957.e943</lpage><pub-id pub-id-type="doi">10.1016/j.jhsa.2016.07.113</pub-id><pub-id pub-id-type="pmid">27692801</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name><name name-style="western"><surname>Goesling</surname><given-names>J</given-names></name><name name-style="western"><surname>Moser</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P</given-names></name><name name-style="western"><surname>Englesbe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></name><name name-style="western"><surname>Kheterpal</surname><given-names>S</given-names></name><name name-style="western"><surname>Nallamothu</surname><given-names>BK</given-names></name></person-group><article-title>New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults</article-title><source>JAMA Surg</source><year>2017</year><volume>152</volume><issue>6</issue><fpage>e170504</fpage><pub-id pub-id-type="doi">10.1001/jamasurg.2017.0504</pub-id><pub-id pub-id-type="pmid">28403427</pub-id><pub-id pub-id-type="pmcid">PMC7050825</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Englesbe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name><name name-style="western"><surname>Smerage</surname><given-names>JB</given-names></name><name name-style="western"><surname>Griggs</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>H</given-names></name><name name-style="western"><surname>Jeruss</surname><given-names>JS</given-names></name><etal/></person-group><article-title>New persistent opioid use among patients with cancer after curative-intent surgery</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>36</issue><fpage>4042</fpage><lpage>4049</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.74.1363</pub-id><pub-id pub-id-type="pmid">29048972</pub-id><pub-id pub-id-type="pmcid">PMC5736238</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Harbaugh CM, Lee JS, Hu HM, McCabe SE, Voepel-Lewis T, Englesbe MJ, Brummett CM, Waljee JF. Persistent Opioid Use Among Pediatric Patients After Surgery. Pediatrics 2018;141(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2017-2439</pub-id><pub-id pub-id-type="pmcid">PMC7053700</pub-id><pub-id pub-id-type="pmid">29203521</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>KG</given-names></name><name name-style="western"><surname>Harbaugh</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Vercler</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name></person-group><article-title>Persistent Opioid Use Among Children, Adolescents, and Young Adults After Common Cleft Operations</article-title><source>J Craniofac Surg</source><year>2018</year><volume>29</volume><issue>7</issue><fpage>1697</fpage><lpage>1701</lpage><pub-id pub-id-type="doi">10.1097/SCS.0000000000004762</pub-id><pub-id pub-id-type="pmid">30059422</pub-id><pub-id pub-id-type="pmcid">PMC6173989</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brescia</surname><given-names>AA</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mazurek</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ward</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JSJ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name><name name-style="western"><surname>Lagisetty</surname><given-names>PA</given-names></name><name name-style="western"><surname>Lagisetty</surname><given-names>KH</given-names></name></person-group><article-title>Factors associated with new persistent opioid usage after lung resection</article-title><source>Ann Thorac Surg</source><year>2019</year><volume>107</volume><issue>2</issue><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.08.057</pub-id><pub-id pub-id-type="pmid">30316852</pub-id><pub-id pub-id-type="pmcid">PMC7136012</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brescia</surname><given-names>AA</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Englesbe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Lagisetty</surname><given-names>PA</given-names></name><name name-style="western"><surname>Lagisetty</surname><given-names>KH</given-names></name></person-group><article-title>Impact of Prescribing on New Persistent Opioid Use After Cardiothoracic Surgery</article-title><source>Ann Thorac Surg</source><year>2019</year><volume>108</volume><issue>4</issue><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2019.06.019</pub-id><pub-id pub-id-type="pmid">31447051</pub-id><pub-id pub-id-type="pmcid">PMC6755048</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Thiels CA, Habermann EB, Hooten WM, Jeffery MM. Chronic use of tramadol after acute pain episode: cohort study BMJ. 2019;365:l1849.&#160;10.1136/bmj.l1849.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l1849</pub-id><pub-id pub-id-type="pmcid">PMC6514531</pub-id><pub-id pub-id-type="pmid">31088782</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roughead</surname><given-names>EE</given-names></name><name name-style="western"><surname>Lim</surname><given-names>R</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>E</given-names></name><name name-style="western"><surname>Moffat</surname><given-names>AK</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>NL</given-names></name></person-group><article-title>Persistence with opioids post discharge from hospitalisation for surgery in Australian adults: a retrospective cohort study</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><issue>4</issue><fpage>e023990</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-023990</pub-id><pub-id pub-id-type="pmid">30992289</pub-id><pub-id pub-id-type="pmcid">PMC6500207</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Berger I, Strother M, Talwar R, Ziemba J, Wirtalla C, Xia L, Guzzo T, Delgado MK, Kelz R. National variation in opioid prescription fills and long-term use in opioid na&#239;ve patients after urological surgery. J Urol. 2019;202(5):1036&#8211;43. 10.1097/JU.0000000000000343.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JU.0000000000000343</pub-id><pub-id pub-id-type="pmid">31112103</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gil</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gunaseelan</surname><given-names>V</given-names></name><name name-style="western"><surname>DeFroda</surname><given-names>SF</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bedi</surname><given-names>A</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name></person-group><article-title>Risk of prolonged opioid use among opioid-na&#239;ve patients after common shoulder arthroscopy procedures</article-title><source>Am J Sports Med</source><year>2019</year><volume>47</volume><issue>5</issue><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1177/0363546518819780</pub-id><pub-id pub-id-type="pmid">30735622</pub-id><pub-id pub-id-type="pmcid">PMC7303922</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Wright JDMD, Huang YMDMPH, Melamed AMDMPH, Tergas AIMDMPH, St. Clair CMMD, Hou JYMD, Khoury-Collado FMD, Ananth CVPMPH, Neugut AIMDP, Hershman DLMD, et al. Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstet Gynecol. 2019;134(2):250&#8211;60.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000003358</pub-id><pub-id pub-id-type="pmid">31306333</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Bicket MC, Murimi IB, Mansour O, Wu CL, Alexander GC. Association of new opioid continuation with surgical specialty and type in the United States. Am J Surg. 2019;218(5):818&#8211;27. 10.1016/j.amjsurg.2019.04.010.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjsurg.2019.04.010</pub-id><pub-id pub-id-type="pmid">31023548</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gossett</surname><given-names>TD</given-names></name><name name-style="western"><surname>Finney</surname><given-names>FT</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Walton</surname><given-names>DM</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>JR</given-names></name></person-group><article-title>New Persistent Opioid Use and Associated Risk Factors Following Treatment of Ankle Fractures</article-title><source>Foot Ankle Int</source><year>2019</year><volume>40</volume><issue>9</issue><fpage>1043</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1177/1071100719851117</pub-id><pub-id pub-id-type="pmid">31132877</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>A</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><name name-style="western"><surname>Sun</surname><given-names>EC</given-names></name><name name-style="western"><surname>Bambos</surname><given-names>N</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>TA</given-names></name></person-group><article-title>Incidence of and Factors Associated With Prolonged and Persistent Postoperative Opioid Use in Children 0&#8211;18 Years of Age</article-title><source>Anesth Analg</source><year>2020</year><volume>131</volume><issue>4</issue><fpage>1237</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000004823</pub-id><pub-id pub-id-type="pmid">32925345</pub-id><pub-id pub-id-type="pmcid">PMC7723784</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>CR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khurshan</surname><given-names>F</given-names></name><name name-style="western"><surname>Groeneveld</surname><given-names>PW</given-names></name><name name-style="western"><surname>Desai</surname><given-names>ND</given-names></name></person-group><article-title>Development of Persistent Opioid Use After Cardiac Surgery</article-title><source>JAMA Cardiol</source><year>2020</year><volume>5</volume><issue>8</issue><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1445</pub-id><pub-id pub-id-type="pmid">32584934</pub-id><pub-id pub-id-type="pmcid">PMC7301303</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>KC</given-names></name><name name-style="western"><surname>Canner</surname><given-names>JK</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>GJR</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>JS</given-names></name><name name-style="western"><surname>Grant</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sussman</surname><given-names>MS</given-names></name></person-group><article-title>New Persistent Opioid Use After Aortic and Mitral Valve Surgery in Commercially Insured Patients</article-title><source>Ann Thorac Surg</source><year>2020</year><volume>110</volume><issue>3</issue><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2019.12.031</pub-id><pub-id pub-id-type="pmid">32004502</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Clement KC, Canner JK, Sussman MS, Hicks CW, Sandhu HK, Estrera AL, Coselli JS, Chatterjee S. Persistent Opioid Use After Open Aortic Surgery: Risk Factors, Costs and Consequences. Ann Thorac Surg. 2020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.athoracsur.2020.11.021</pub-id><pub-id pub-id-type="pmcid">PMC9853230</pub-id><pub-id pub-id-type="pmid">33338481</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>KC</given-names></name><name name-style="western"><surname>Canner</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lawton</surname><given-names>JS</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>GJR</given-names></name><name name-style="western"><surname>Grant</surname><given-names>MC</given-names></name><name name-style="western"><surname>Sussman</surname><given-names>MS</given-names></name></person-group><article-title>Predictors of new persistent opioid use after coronary artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2020</year><volume>160</volume><issue>4</issue><fpage>954</fpage><lpage>963.e954</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2019.09.137</pub-id><pub-id pub-id-type="pmid">32007246</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santosa</surname><given-names>KB</given-names></name><name name-style="western"><surname>Hu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Brummett</surname><given-names>CM</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>MA</given-names></name><name name-style="western"><surname>Englesbe</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>EA</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name></person-group><article-title>New persistent opioid use among older patients following surgery: A Medicare claims analysis</article-title><source>Surgery</source><year>2020</year><volume>167</volume><issue>4</issue><fpage>732</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2019.04.016</pub-id><pub-id pub-id-type="pmid">31349994</pub-id><pub-id pub-id-type="pmcid">PMC7216555</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delaney</surname><given-names>LD</given-names></name><name name-style="western"><surname>Gunaseelan</surname><given-names>V</given-names></name><name name-style="western"><surname>Rieck</surname><given-names>H</given-names></name><name name-style="western"><surname>Dupree</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hallstrom</surname><given-names>BR</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>JF</given-names></name></person-group><article-title>High-Risk Prescribing Increases Rates of New Persistent Opioid Use in Total Hip Arthroplasty Patients</article-title><source>J Arthroplasty</source><year>2020</year><volume>35</volume><issue>9</issue><fpage>2472</fpage><lpage>2479.e2472</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2020.04.019</pub-id><pub-id pub-id-type="pmid">32389404</pub-id><pub-id pub-id-type="pmcid">PMC8289485</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Beyene KA, Chan AHY, Aquite OM, Kumar M, Moore S, Park YJ, Ruohonen T, Gong J: Postdischarge opioid use and persistent use after general surgery: A retrospective study. Surgery. 2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2022.02.017</pub-id><pub-id pub-id-type="pmid">35387745</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argyriou</surname><given-names>E</given-names></name><name name-style="western"><surname>Um</surname><given-names>M</given-names></name><name name-style="western"><surname>Carron</surname><given-names>C</given-names></name><name name-style="western"><surname>Cyders</surname><given-names>MA</given-names></name></person-group><article-title>Age and impulsive behavior in drug addiction: A review of past research and future directions</article-title><source>Pharmacol Biochem Behav</source><year>2018</year><volume>164</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2017.07.013</pub-id><pub-id pub-id-type="pmid">28778737</pub-id><pub-id pub-id-type="pmcid">PMC5797988</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Malkawi WA, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem AM. Formulation Challenges and Strategies to Develop Pediatric Dosage Forms. Children (Basel). 2022;9(4):488. 10.3390/children9040488.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/children9040488</pub-id><pub-id pub-id-type="pmcid">PMC9027946</pub-id><pub-id pub-id-type="pmid">35455532</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinonara</surname><given-names>K</given-names></name><name name-style="western"><surname>Ugawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Arataki</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakahara</surname><given-names>S</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>K</given-names></name></person-group><article-title>Charlson comorbidity index is predictive of postoperative clinical outcome after single-level posterior lumbar interbody fusion surgery</article-title><source>J Orthop Surg Res</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>235</fpage><pub-id pub-id-type="doi">10.1186/s13018-021-02377-7</pub-id><pub-id pub-id-type="pmid">33785033</pub-id><pub-id pub-id-type="pmcid">PMC8008557</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>Charlson comorbidity index for evaluati&#959;n &#959;f the outcomes of elderly patients undergoing laparoscopic surgery for colon cancer</article-title><source>J buon</source><year>2017</year><volume>22</volume><issue>3</issue><fpage>686</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">28730775</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goto</surname><given-names>T</given-names></name><name name-style="western"><surname>Kitahara</surname><given-names>A</given-names></name><name name-style="western"><surname>Koike</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuchida</surname><given-names>M</given-names></name></person-group><article-title>Impact of postoperative complications on outcomes of second surgery for second primary lung cancer</article-title><source>Surg Today</source><year>2020</year><volume>50</volume><issue>11</issue><fpage>1452</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1007/s00595-020-02038-y</pub-id><pub-id pub-id-type="pmid">32488477</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Rivara</surname><given-names>FP</given-names></name><name name-style="western"><surname>Nathens</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jurkovich</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>EJ</given-names></name></person-group><article-title>Development and validation of the mortality risk for trauma comorbidity index</article-title><source>Ann Surg</source><year>2010</year><volume>252</volume><issue>2</issue><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181df03d6</pub-id><pub-id pub-id-type="pmid">20622665</pub-id><pub-id pub-id-type="pmcid">PMC3039002</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupp</surname><given-names>T</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>KA</given-names></name></person-group><article-title>Inadequate analgesia in emergency medicine</article-title><source>Ann Emerg Med</source><year>2004</year><volume>43</volume><issue>4</issue><fpage>494</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2003.11.019</pub-id><pub-id pub-id-type="pmid">15039693</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savage</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kirsh</surname><given-names>KL</given-names></name><name name-style="western"><surname>Passik</surname><given-names>SD</given-names></name></person-group><article-title>Challenges in using opioids to treat pain in persons with substance use disorders</article-title><source>Addict Sci Clin Pract</source><year>2008</year><volume>4</volume><issue>2</issue><fpage>4</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1151/ascp08424</pub-id><pub-id pub-id-type="pmid">18497713</pub-id><pub-id pub-id-type="pmcid">PMC2797112</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theunissen</surname><given-names>M</given-names></name><name name-style="western"><surname>Peters</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>J</given-names></name><name name-style="western"><surname>Gramke</surname><given-names>H-F</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>MA</given-names></name></person-group><article-title>Preoperative Anxiety and Catastrophizing: A Systematic Review and Meta-analysis of the Association With Chronic Postsurgical Pain</article-title><source>Clin J Pain</source><year>2012</year><volume>28</volume><issue>9</issue><fpage>819</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1097/AJP.0b013e31824549d6</pub-id><pub-id pub-id-type="pmid">22760489</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>EC</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>A</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>K</given-names></name><name name-style="western"><surname>Darnall</surname><given-names>BD</given-names></name><name name-style="western"><surname>Baker</surname><given-names>LC</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>S</given-names></name></person-group><article-title>Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis</article-title><source>BMJ</source><year>2017</year><volume>356</volume><fpage>j760</fpage><pub-id pub-id-type="doi">10.1136/bmj.j760</pub-id><pub-id pub-id-type="pmid">28292769</pub-id><pub-id pub-id-type="pmcid">PMC5421443</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>WB</given-names></name><name name-style="western"><surname>Willis</surname><given-names>LE</given-names></name><name name-style="western"><surname>Medvedev</surname><given-names>S</given-names></name><name name-style="western"><surname>Carson</surname><given-names>SS</given-names></name></person-group><article-title>The implications of long-term acute care hospital transfer practices for measures of in-hospital mortality and length of stay</article-title><source>Am J Respir Crit Care Med</source><year>2012</year><volume>185</volume><issue>1</issue><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1164/rccm.201106-1084OC</pub-id><pub-id pub-id-type="pmid">21940788</pub-id><pub-id pub-id-type="pmcid">PMC3361349</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Bilimoria</surname><given-names>KY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>CY</given-names></name><name name-style="western"><surname>Richards</surname><given-names>K</given-names></name><name name-style="western"><surname>Hall</surname><given-names>BL</given-names></name></person-group><article-title>Variability in length of stay after colorectal surgery: assessment of 182 hospitals in the national surgical quality improvement program</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><issue>6</issue><fpage>901</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181b2a948</pub-id><pub-id pub-id-type="pmid">19953710</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Oelreich</surname><given-names>E</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name><name name-style="western"><surname>Brattstrom</surname><given-names>O</given-names></name><name name-style="western"><surname>Sjolund</surname><given-names>KF</given-names></name><name name-style="western"><surname>Discacciati</surname><given-names>A</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>E</given-names></name><name name-style="western"><surname>Oldner</surname><given-names>A</given-names></name></person-group><article-title>Risk factors and outcomes of chronic opioid use following trauma</article-title><source>Br J Surg</source><year>2020</year><volume>107</volume><issue>4</issue><fpage>413</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1002/bjs.11507</pub-id><pub-id pub-id-type="pmid">32031251</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>